BioNTech’s acquisition of CureVac is a strategic move to expand its capabilities in mRNA technology, particularly in cancer immunotherapy, with significant implications for the future of mRNA-based therapies.

CureVac NV, a clinical-stage biopharmaceutical company, navigates financial challenges while advancing its mRNA-based therapies, with notable clinical progress and regulatory milestones in lung cancer and glioblastoma treatment.

CureVac NV, a clinical-stage biopharmaceutical company, has released its Q1 2025 financial results, highlighting FDA approval for its sqNCLC treatment candidate and progress in its glioblastoma study.

CureVac NV’s recent patent victory has bolstered investor confidence, but the company still faces market uncertainty and must navigate ongoing challenges to achieve sustained growth.

CureVac NV has received a positive patent decision from the European Patent Office, dismissing opposition from BioNTech SE and others, in a significant development in their ongoing legal dispute.

CureVac NV has received a favorable decision from the European Patent Office, dismissing opposition to its patent and potentially boosting its market position and financial performance.